Paper Details

  1. Home
  2. Paper Details

Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial.

Author: ArnedosM, ArteagaC L, BellJ S K, BhaveM, BidardF-C, BoseR, BrufskyA, BurkardM E, ChiaS, CrownJ, DiPrimeoD, EliL D, FrazierA, Gal-YamE N, GambardellaV, Garcia-SaenzJ Á, GoldmanJ W, Guerrero-ZotanoA, HankerA B, HurvitzS A, JhaveriK, LoiS, MaC, ParkH, PetersonL, Piha-PaulS A, PratA, RapaelA, ReidS, SauraC, SolitD B, SpanggaardI, StemmerS M, SugaJ M, UnniN, VinayakS, WaismanJ, WildiersH, WongA, YangE S, YeD, de MiguelM J

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.
Research Support, N.I.H., ExtramuralResearch funding provided by the NIH to external research institutions and researchers.
Research Support, Non-U.S. Gov'tResearch funding provided by government agencies outside the United States.

Overview

Neratinib is a drug that is used to treat HER2-mutant metastatic breast cancer. A study investigated the efficacy and safety of neratinib in patients with HER2-mutant metastatic breast cancer.
Paper Details　
Original Abstract of the Article :
HER2 mutations are targetable alterations in patients with hormone receptor-positive (HR+) metastatic breast cancer (MBC). In the SUMMIT basket study, patients with HER2-mutant MBC received neratinib monotherapy, neratinib + fulvestrant, or neratinib + fulvestrant + trastuzumab (N + F + T). We repor...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1016/j.annonc.2023.08.003

データ提供：米国国立医学図書館（NLM）

Targeted Therapy for HER2-Mutant Breast Cancer: A Desert Oasis of Hope

The journey through breast cancer treatment is often a desert of uncertainty and challenges. This study explores the potential of [neratinib] in combination with other medications for patients with [hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer]. The researchers investigated the efficacy of [neratinib monotherapy], [neratinib + fulvestrant], and [neratinib + fulvestrant + trastuzumab] in a group of 71 patients. Their findings suggest that [neratinib + fulvestrant + trastuzumab] may be a promising treatment option for this specific type of breast cancer.

Neratinib: A Potential Game-Changer for HER2-Mutant Breast Cancer

This study offers a potential oasis of hope for patients with HER2-mutant breast cancer. The findings suggest that neratinib, in combination with fulvestrant and trastuzumab, could offer a more targeted and effective treatment approach for this specific type of breast cancer. This research could lead to improved outcomes for patients navigating the challenging desert of breast cancer treatment.

Navigating the Desert of Breast Cancer Treatment: A New Compass

This study underscores the importance of targeted therapy in the fight against breast cancer. The findings suggest that neratinib could be a valuable weapon in the arsenal against HER2-mutant breast cancer, offering a potential path towards better outcomes for patients. This research provides a new compass to guide us through the desert of breast cancer treatment, bringing us closer to a future where we can effectively combat this formidable disease.

Dr. Camel's Conclusion

This research explores the potential of neratinib in combination with other medications as a promising treatment option for HER2-mutant breast cancer. The desert of breast cancer treatment can be a daunting and uncertain landscape, but research like this provides a beacon of hope, guiding us towards more targeted and effective therapies. We must continue to seek new oases of knowledge and innovation in the fight against this formidable disease.

Date :
  1. Date Completed 2023-11-09
  2. Date Revised 2023-11-19
Further Info :

Pubmed ID

37597578

DOI: Digital Object Identifier

10.1016/j.annonc.2023.08.003

Related Literature

Article Analysis
・Effects of neratinib
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.